• Content
  • Search
  • Navigation
  • Sitemap
  • About us
    • About us
    • Who we are
    • Our model
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Portfolio data
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • AGTC
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
      • Kesmalea Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • Neogene Therapeutics
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chair, SIML
    • Our approach to sustainability reporting
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
      • Sustainability within the Syncona portfolio
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
      • Syncona TCFD disclosure
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment proposition
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact
  1. News and Insights
  2. Insights & articles

Syncona FY20: Martin Murphy discusses FY20 results

Published

11.06.20

Share this page
Further reading
  • Syncona
Back to News and Insights

Related Insights and articles

23.10.19

Building Syncona’s Gene Therapy platform

  • Found, build, fund
  • Syncona
11.06.20

Syncona FY20: Martin Murphy discusses the outlook for Syncona

  • Syncona
01.03.23

Good science must survive in challenging markets

  • World class leadership
  • Syncona

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

  • RNS alerts
  • Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR
contact@synconaltd.com

  • About us
  • Our people
  • Portfolio
  • Sustainability
  • News and Insights
  • Investors
  • Contact
  • Copyright © Syncona 2023
  • Accessibility
  • Privacy & cookies
  • Employee privacy notice
  • Third party privacy notice
  • Regulatory publications
  • Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay
  • About us
    • About us
    • Who we are
    • Our model
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Portfolio data
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • AGTC
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
      • Kesmalea Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • Neogene Therapeutics
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chair, SIML
    • Our approach to sustainability reporting
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
      • Sustainability within the Syncona portfolio
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
      • Syncona TCFD disclosure
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment proposition
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact
GBX 149.20
Change: +4.20 (+2.90%)

Search